1. Bufalin reverses acquired drug resistance by inhibiting stemness in colorectal cancer cells
    Jian Sun et al, 2017, Oncology Reports CrossRef
  2. An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
    Qingmei Ye et al, 2023, Frontiers in Pharmacology CrossRef
  3. Molecular mechanisms of bufadienolides and their novel strategies for cancer treatment
    Li-Juan Deng et al, 2020, European Journal of Pharmacology CrossRef

  4. Multidrug Resistance of Gastric Cancer: The Mechanisms and Chinese Medicine Reversal Agents


    Wen-Jie Huang et al, 2020, Cancer Management and Research CrossRef
  5. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment
    Quan Gao et al, 2022, Advanced Drug Delivery Reviews CrossRef
  6. Anticancer and Antiviral Properties of Cardiac Glycosides: A Review to Explore the Mechanism of Actions
    Dhanasekhar Reddy et al, 2020, Molecules CrossRef
  7. Sageone, a diterpene from Rosmarinus officinalis, synergizes with cisplatin cytotoxicity in SNU-1 human gastric cancer cells
    Sabina Shrestha et al, 2016, Phytomedicine CrossRef
  8. The signaling pathways and targets of natural products from traditional Chinese medicine treating gastric cancer provide new candidate therapeutic strategies
    Yile Liao et al, 2023, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
  9. Ubenimex induces autophagy inhibition and EMT suppression to overcome cisplatin resistance in GC cells by perturbing the CD13/EMP3/PI3K/AKT/NF-κB axis
    Qie Guo et al, 2019, Aging CrossRef
  10. Bufalin serves as a pharmaceutic that mitigates drug resistance
    Linxuan Miao et al, 2023, Drug Metabolism Reviews CrossRef
  11. SCARA3 inhibits cell proliferation and EMT through AKT signaling pathway in lung cancer
    Jeeho Kim et al, 2022, BMC Cancer CrossRef
  12. RUNDC3A regulates SNAP25-mediated chemotherapy resistance by binding AKT in gastric neuroendocrine carcinoma (GNEC)
    Pengchen Chen et al, 2022, Cell Death Discovery CrossRef
  13. Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer
    Fei Cao et al, 2019, Toxicology and Applied Pharmacology CrossRef
  14. Research Progress in Pharmacological Activities and Applications of Cardiotonic Steroids
    Junwei Ren et al, 2022, Frontiers in Pharmacology CrossRef
  15. Sensational site: the sodium pump ouabain-binding site and its ligands
    Mordecai P. Blaustein et al, 2024, American Journal of Physiology-Cell Physiology CrossRef
  16. Bufalin inhibits gastric cancer invasion and metastasis by down-regulating Wnt/ASCL2 expression
    Jie Wang et al, 2018, Oncotarget CrossRef
  17. Development, Optimization, and Pharmacokinetics Study of Bufalin/Nintedanib Co-loaded Modified Albumin Sub-microparticles Fabricated by Coaxial Electrostatic Spray Technology
    Peng Chen et al, 2021, AAPS PharmSciTech CrossRef
  18. Bufalin for an innovative therapeutic approach against cancer
    Laura Soumoy et al, 2022, Pharmacological Research CrossRef
  19. New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin
    Chien-shan Cheng et al, 2019, Cancer Cell International CrossRef
  20. Response prediction to oxaliplatin plus 5‑fluorouracil chemotherapy in patients with colorectal cancer using a four‑protein immunohistochemical model
    Junjie Gu et al, 2019, Oncology Letters CrossRef